Xenon Pharmaceuticals (XENE) Competitors $33.44 +2.04 (+6.50%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. VTRS, QGEN, ASND, ROIV, LNTH, TGTX, RVMD, BBIO, LEGN, and BPMCShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Legend Biotech Blueprint Medicines Viatris (NASDAQ:VTRS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Do analysts rate VTRS or XENE? Viatris presently has a consensus target price of $10.50, suggesting a potential upside of 37.61%. Xenon Pharmaceuticals has a consensus target price of $57.38, suggesting a potential upside of 71.58%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, VTRS or XENE? Viatris has higher revenue and earnings than Xenon Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.62$54.70M-$0.53-14.40Xenon Pharmaceuticals$9.43M271.43-$182.39M-$3.02-11.07 Is VTRS or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-5.87% 16.46% 7.09% Xenon Pharmaceuticals N/A -24.69%-23.68% Do insiders & institutionals have more ownership in VTRS or XENE? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer VTRS or XENE? In the previous week, Viatris had 48 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 57 mentions for Viatris and 9 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.10 beat Viatris' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 2 Very Positive mention(s) 7 Positive mention(s) 39 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Neutral Xenon Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community favor VTRS or XENE? Xenon Pharmaceuticals received 400 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.92% of users gave Xenon Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformViatrisOutperform Votes2334.85% Underperform Votes4365.15% Xenon PharmaceuticalsOutperform Votes42369.92% Underperform Votes18230.08% Which has more volatility and risk, VTRS or XENE? Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. SummaryXenon Pharmaceuticals beats Viatris on 11 of the 18 factors compared between the two stocks. Remove Ads Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56B$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-11.866.7721.6817.78Price / Sales271.43228.59376.3394.51Price / CashN/A65.6738.1534.64Price / Book2.365.886.443.99Net Income-$182.39M$141.32M$3.20B$247.24M7 Day Performance18.46%8.48%9.01%8.29%1 Month Performance-5.32%-12.84%-6.09%-5.37%1 Year Performance-19.05%-12.40%10.72%-0.24% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals1.8773 of 5 stars$33.44+6.5%$57.38+71.6%-19.0%$2.56B$9.43M-11.86210Positive NewsVTRSViatris2.9578 of 5 stars$7.61-0.1%$10.50+38.0%-32.7%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.4869 of 5 stars$40.33+5.4%$47.71+18.3%+8.3%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3006 of 5 stars$140.14-1.8%$204.64+46.0%+6.5%$8.50B$363.64M-19.741,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.6189 of 5 stars$9.26-2.1%$17.50+89.0%-6.9%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.4105 of 5 stars$95.45+5.0%$129.43+35.6%+68.0%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3134 of 5 stars$37.25-0.3%$40.67+9.2%+171.3%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.812 of 5 stars$31.40+0.3%$65.23+107.7%+1.1%$5.84B$742,000.00-8.75250Positive NewsGap UpHigh Trading VolumeBBIOBridgeBio Pharma4.5785 of 5 stars$30.67-2.2%$52.64+71.6%+29.9%$5.83B$221.90M-10.76400Positive NewsLEGNLegend Biotech2.405 of 5 stars$30.25-5.5%$79.00+161.2%-39.3%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6147 of 5 stars$80.20-1.8%$124.95+55.8%-5.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Viatris Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts